ABC of mens health

June 19, 2008

Maxi-K Gene Transfer May Prove To Be Safe And Effective Erectile Dysfunction Treatment

Filed under: Uncategorized — Tags: , — poster @ 5:35 pm

Maxi-K gene therapy may be a safe and effective future option for men whose erectile dysfunction (ED) is not treatable with oral therapy. Two studies presented at the 103rd Annual Scientific Meeting of the American Urological Association (AUA) may give hope to these individuals. Researchers will present their findings to reporters in a special press conference on May 20, 2008 at 10 a.m.
(more…)

Federal Authorities Seize More Than 100,000 Dollars Of Unapproved Drugs Marketed As “Natural Supplements”

Filed under: Uncategorized — Tags: , — poster @ 5:35 pm

At the request of the U.S. Food and Drug Administration, U.S. Marshals seized more than 14,000 dosage units of Shangai Regular, Shangai Ultra, Super Shangai, Natural?« Super Plus, and Lady Shangai. Although labeled as natural supplements, the seized products were all marketed to treat erectile dysfunction (ED), impotency, and/or to provide sexual enhancement, which caused them to be drugs under the Federal Food, Drug, (more…)

Multifunctional nanoparticles image, target, and treat tumors

Filed under: Uncategorized — Tags: , — poster @ 5:35 pm

Men’s Health News
Encapsulating magnetic iron oxide nanoparticles within a silica shell has yielded a new multifunctional nanoparticle that has the potential to image, target, and treat tumors with water-insoluble anticancer drugs. Kaufen generishe levitra A report of this work appears in the journal ACS Nano.
Jeffery Zink, Ph.D., led a research (more…)

Scientists cast doubt on value of screening for prostate cancer

Filed under: Uncategorized — Tags: , — poster @ 5:35 pm

Men’s Health News
Even though deaths from prostate cancer death have fallen in the U.S. since screening became more common, new research is suggesting that this does not justify the need for such tests.
According to a team of scientists from the University of Bristol many other factors could be involved such as different treatment (more…)

Hello world!

Filed under: Uncategorized — a_bc_7cos_info @ 4:40 pm

Welcome to Mu.on-biz.info. This is your first post. Edit or delete it, then start blogging!

February 16, 2008

Male breast cancer

Filed under: Uncategorized — poster @ 8:35 am

Men’s Health News
Mammography and sonography findings help doctors identify and appropriately treat breast cancer in men, according to a study performed at the University of Texas M.D. Cancer Center in Houston, TX.
Image findings from 57 male patients who were diagnosed with (more…)

February 15, 2008

Link found between cryptorchidism and genetic mutations

Filed under: Uncategorized — poster @ 11:35 pm

Men’s Health News
A small percentage of males born with cryptorchidism (failure of one or both testicles to descend into the scrotum), the most frequent congenital birth defect in male children, are more likely to have genetic mutations, including for a syndrome that is a common genetic cause of infertility, according to a study in the November 19 issue of JAMA, the Journal of the American Medical Association.
(more…)

Australian men need the ‘right doctors’

Filed under: Uncategorized — poster @ 6:35 am

Men’s Health News
Researchers from the University of Adelaide say regardless of the preconceived stereotype surrounding men and their health, Australian men are interested in talking about their health with the ‘right people’ and most men do not like the way that many doctors work.
The researchers from the University’s Freemasons Foundation Centre for Men’s (more…)

February 14, 2008

Sciele Pharma And Plethora Solutions Announce Final Analysis Of PSD502 For Premature Ejaculation; All Primary And Secondary Endpoints Met In Phase III

Filed under: Uncategorized — Tags: , , , , — poster @ 9:35 pm

Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE), the specialist developer of products for the treatment and management of urological disorders, today announced the final analysis of its European Phase III double-blind placebo-controlled study of PSD502 for the treatment of premature ejaculation (’PE’). (more…)

« Older Posts

Powered by WordPress